Check Cap Ltd (NASDAQ:CHEK) Short Interest Update

Check Cap Ltd (NASDAQ:CHEK) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 712,000 shares, a decline of 14.1% from the June 30th total of 828,900 shares. Approximately 20.1% of the company’s shares are sold short. Based on an average daily volume of 123,400 shares, the days-to-cover ratio is presently 5.8 days.

A number of analysts have recently weighed in on the company. Zacks Investment Research raised Check Cap from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Check Cap in a report on Wednesday, July 10th.

An institutional investor recently raised its position in Check Cap stock. Renaissance Technologies LLC increased its position in shares of Check Cap Ltd (NASDAQ:CHEK) by 24.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 307,468 shares of the medical research company’s stock after acquiring an additional 60,026 shares during the quarter. Renaissance Technologies LLC owned approximately 19.16% of Check Cap worth $652,000 as of its most recent filing with the SEC.

Shares of CHEK traded down $0.01 during mid-day trading on Thursday, hitting $1.91. 107,563 shares of the company’s stock were exchanged, compared to its average volume of 213,621. Check Cap has a fifty-two week low of $1.62 and a fifty-two week high of $4.50. The company has a 50 day simple moving average of $2.11.

Check Cap (NASDAQ:CHEK) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.41) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.05. As a group, sell-side analysts forecast that Check Cap will post -1.66 earnings per share for the current fiscal year.

Check Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Read More: Economic Reports

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.